|
|
|
|
|
Last Trade
|
Last Trade:
$4.40
|
Change:
0.04 (0.92%)
|
Trade Time:
Feb 15
|
Market Cap:
$281.33M
|
|
|
|
|
|
|
Description of Business
|
|
Depomed is a specialty pharmaceutical company focused on pain and other central
nervous system (CNS) conditions. Our current specialty pharmaceutical business
includes the following three products which we market in the United States
(U.S.):
· Gralise® (gabapentin), a oncedaily product for the management of postherpetic
neuralgia (PHN), that we launched in October 2011.
· CAMBIA® (diclofenac potassium for oral solution), a nonsteroidal
antiinflammatory drug for the acute treatment of migraine attacks, that we
acquired in December 2013.
· Zipsor® (diclofenac potassium) liquid filled capsules, a nonsteroidal
antiinflammatory drug for the treatment of mild to moderate acute pain, that
we acquired in June 2012.
|
|
|
|